Given that PP2A activity is suppressed in cancers either through overexpression of inhibitory proteins or through mutations in PP2A components, there is an interest in developing compounds that can reactivate PP2A for cancer treatment (Westermarck & Neel, 2020; Vainonen et al, 2021). Here, PTPA is linked to cancer.